Aurobindo Pharma Limited (NSE: AUROPHARMA) is pleased to announce the receipt of final approval from the US Food & Drug Administration (USFDA) to manufacture and market Perampanel Tablets, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. These tablets are bioequivalent and therapeutically equivalent to the reference listed drug, Fycompa® Tablets, of Catalyst Pharmaceuticals, Inc. The product will be manufactured at Unit -IV of APL Healthcare, a wholly-owned subsidiary of the Company, and is set to launch in Q3FY27. The approved product has an estimated market size of US$ 67 million for the twelve months ending August 2026, according to IQVIA MAT.

Significance of Approval

This approval marks a significant milestone for Aurobindo Pharma as it expands its portfolio of CNS products. Perampanel Tablets are indicated for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 4 years and older and as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older.

Company’s Growth and Future Prospects

With this approval, Aurobindo Pharma now has a total of 599 ANDA approvals from USFDA. The company continues to strengthen its position in the global pharmaceutical market with its robust product portfolio spread over seven major therapeutic areas. Aurobindo Pharma’s commitment to innovation and quality is evident in its extensive list of manufacturing and packaging facilities approved by leading regulatory agencies worldwide.

Aurobindo Pharma Limited remains dedicated to its mission of delivering high-quality, affordable medications to patients globally. With the launch of Perampanel Tablets, the company is poised to further its growth and contribute to improved patient outcomes in the epilepsy treatment landscape.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Aurobindo Pharma Limited

Aurobindo Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Aurobindo posts a 3.5% three-month gain, but softens in the last few weeks. Revenue grows at 10.7% and profits at 22.1% CAGR. The market consistently rewards this kind of compounding. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock gives back 0.4% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Both the business and the stock move in the right direction. Revenue grows at 10.7%, profits at 22.1%, and the PEG sits at 1.17 — below its growth rate. That combination is rare. Check Fundamentals of Aurobindo Pharma Limited.

Sun Pharmaceutical Industries Limited (SUNPHARMA) announced today that LEQSELVI® (deuruxolitinib) will be featured in seven presentations at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, including a featured oral presentation reporting long-term safety results from a European open-label extension (OLE) study evaluating up to two years of treatment in adults with severe alopecia areata (AA). The featured oral presentation found that the safety profile of LEQSELVI remained consistent with previous clinical experience through up to two years of open-label treatment in adults with severe AA.

Long-Term Efficacy and Safety

Most treatment-emergent adverse events were mild or moderate in severity, treatment discontinuations due to adverse events were uncommon, and no deaths, thrombosis, or major adverse cardiovascular events were reported among patients receiving the FDA-approved dose of 8 mg twice-daily. Long-term efficacy analyses presented in a poster also showed durable scalp hair regrowth through Week 108 in patients receiving LEQSELVI in the European OLE. Of OLE baseline treatment responders maintaining response at Week 52 and continuing in the study, 93.9% maintained response at Week 108. Many patients (76.6%) who were baseline nonresponders achieved response by Week 52.

Clinical Significance

“Severe alopecia areata is a chronic autoimmune disease, making long-term treatment considerations particularly important for both patients and their clinicians,” said Arash Mostaghimi, MD, MPA, MPH, FAAD, Vice Chair of Clinical Trials and Innovation and Associate Professor of Dermatology at Brigham and Women’s Hospital. “Collectively, these data show durable efficacy and maintenance of response for deuruxolitinib over time and reinforce the growing body of evidence supporting its use as a long-term treatment option for eligible adults.”

The LEQSELVI data presentation is one of 22 presentations from Sun Pharma across its dermatology and immunology portfolio. LEQSELVI® (deuruxolitinib) 8 mg tablets is an oral selective inhibitor of Janus kinases JAK1 and JAK2 FDA-approved for the treatment of adults with severe alopecia areata.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Sun moves sideways over three months, with neither buyers nor sellers taking control. The PEG reaches 3.38. The stock trades on brand and index weight, not on growth. Premium net margins of 20.2% demonstrate strong cost discipline and a wide competitive moat. The stock holds at 47% of its 52-week range with RSI at 37. In other words, neither side has a clear edge right now. Revenue grows at 10.4% and profits at 10.6% CAGR, with D/E of 0.03. Meanwhile, the stock dips 5.5% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Sun Pharmaceutical Industries Limited.

Global Health Limited (NSE: MEDANTA), one of the largest private multi-specialty tertiary care providers in India, announced the acquisition of a 10,560 sq. metre land parcel in Siddharth Vihar Yojna, Ghaziabad, Uttar Pradesh. The land, allotted by the Uttar Pradesh Housing & Development Board (UPAVP), was secured for approximately ₹165.82 crore through an online auction. This strategic acquisition aims to develop a 350+ bedded hospital, pending customary and statutory approvals and board approval.

Strategic Expansion in Ghaziabad

The proposed hospital is expected to enhance Global Health Limited’s presence in the Delhi-NCR healthcare ecosystem, providing high-quality tertiary and quaternary care services to the rapidly growing population of Ghaziabad and surrounding areas. Ghaziabad, with its large and growing population, increasing urbanization, and strong connectivity with Delhi-NCR, represents a compelling long-term healthcare opportunity. The Siddharth Vihar location offers a platform to establish a large integrated healthcare facility, addressing the growing demand for advanced medical care.

Future Healthcare Footprint

Commenting on the acquisition, Mr. Pankaj Sahni, Group CEO and Director, stated, “We see Ghaziabad as a compelling long-term healthcare opportunity within the broader Delhi-NCR market. The region has undergone significant urban and economic development and continues to see increasing demand for advanced, specialized healthcare services. The Siddharth Vihar land parcel offers us a strategically located platform to potentially develop a large integrated hospital and extend our clinical capabilities to a wider patient catchment.” The proposed hospital will complement Medanta’s existing presence in Noida, strengthening the healthcare network across eastern and central parts of the Delhi-NCR region.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Global Health Limited

Global Health Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Global posts a 9.1% three-month gain, but softens in the last few weeks. The PEG reaches 3.56. The stock trades on brand and index weight, not on growth. The business compounds revenue at 17.2% and profits at 19.5% CAGR. That is strong double-digit growth on both counts. The stock gives back 2.6% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The stock rises 9.1% in three months on 17.2% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Global Health Limited.